| Telomere dysfunction induces metabolic and mitochondrial compromise E Sahin, S Colla, M Liesa, J Moslehi, FL Müller, M Guo, M Cooper, ... Nature 470 (7334), 359-365, 2011 | 1454 | 2011 |
| Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice M Jaskelioff, FL Muller, JH Paik, E Thomas, S Jiang, AC Adams, E Sahin, ... Nature 469 (7328), 102-106, 2011 | 1052 | 2011 |
| Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers GR Hoffman, R Rahal, F Buxton, K Xiang, G McAllister, E Frias, ... Proceedings of the National Academy of Sciences 111 (8), 3128-3133, 2014 | 451 | 2014 |
| Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer J Hu, SS Hwang, M Liesa, B Gan, E Sahin, M Jaskelioff, Z Ding, H Ying, ... Cell 148 (4), 651-663, 2012 | 353 | 2012 |
| Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases Z Ding, CJ Wu, M Jaskelioff, E Ivanova, M Kost-Alimova, A Protopopov, ... Cell 148 (5), 896-907, 2012 | 261 | 2012 |
| Rad54p is a chromatin remodeling enzyme required for heteroduplex DNA joint formation with chromatin M Jaskelioff, S Van Komen, JE Krebs, P Sung, CL Peterson Journal of Biological Chemistry 278 (11), 9212-9218, 2003 | 237 | 2003 |
| Proinvasion metastasis drivers in early-stage melanoma are oncogenes KL Scott, C Nogueira, TP Heffernan, R van Doorn, S Dhakal, JA Hanna, ... Cancer cell 20 (1), 92-103, 2011 | 170 | 2011 |
| SWI-SNF-mediated nucleosome remodeling: role of histone octamer mobility in the persistence of the remodeled state M Jaskelioff, I M. Gavin, CL Peterson, C Logie Molecular and cellular biology 20 (9), 3058-3068, 2000 | 149 | 2000 |
| Chromatin and transcription: histones continue to make their marks M Jaskelioff, CL Peterson Nature cell biology 5 (5), 395-399, 2003 | 109 | 2003 |
| Hyperactivation of MAPK signaling is deleterious to RAS/RAF-mutant melanoma GP Leung, T Feng, FD Sigoillot, FC Geyer, MD Shirley, DA Ruddy, ... Molecular Cancer Research 17 (1), 199-211, 2019 | 64 | 2019 |
| LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors KA Monaco, S Delach, J Yuan, Y Mishina, P Fordjour, E Labrot, D McKay, ... Clinical cancer research 27 (7), 2061-2073, 2021 | 62 | 2021 |
| Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene M Jaskelioff, W Song, J Xia, C Liu, J Kramer, S Koido, SJ Gendler, ... Oncogene 28 (48), 4225-4236, 2009 | 30 | 2009 |
| In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling Z Jagani, G Chenail, K Xiang, G Bushold, HEC Bhang, A Li, GN Elliott, ... Biorxiv, 812628, 2019 | 11 | 2019 |
| Utilizing murine inducible telomerase alleles in the studies of tissue degeneration/regeneration and cancer T Shingu, M Jaskelioff, L Yuan, Z Ding, A Protopopov, M Kost-Alimova, ... Journal of visualized experiments: JoVE, 52599, 2015 | 5 | 2015 |
| Abstract LB-114: RAF inhibitor LXH254 effectively inhibits B-and-CRAF, but not ARAF KA Monaco, S Delach, P Fordjour, S Parikh, Y Feng, M Jaskelioff, D Stuart, ... Cancer Research 79 (13_Supplement), LB-114-LB-114, 2019 | 4 | 2019 |
| Genome unstable murine prostate cancers acquire genomic aberrations and bone metastatic features of the human disease Z Ding, CJ Wu, M Jaskelioff, E Ivanova, M Kost-Alimova, A Protopopov, ... Cell 148 (5), 896, 2012 | 2 | 2012 |
| Quantification of telomere length by FISH and laser scanning cytometry JE Mahoney, E Sahin, M Jaskelioff, L Chin, RA DePinho, AI Protopopov Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues VI …, 2008 | 1 | 2008 |
| Postdoc Mentor Profile M Jaskelioff https://www. novartis. com/our-science/postdoc-program, 2019 | | 2019 |
| Deleterious effects of MAPK pathway hyperactivation in BRAF-mutant melanoma GP Leung, T Feng, MD Shirley, FD Sigoillot, DA Ruddy, AK Freeman, ... Cancer Research 78 (13_Supplement), 965-965, 2018 | | 2018 |
| Markers for ezh2 inhibitors HM Chan, V Gibaja, K Haas, J Jaffe, M Jaskelioff, FP Stegmeier, W Qi US Patent App. 14/785,594, 2016 | | 2016 |
